Navigation Links
OncoMed Anti-Cancer Stem Cell Antibody OMP-21M18 Demonstrates Potent Activity in Preclinical Studies Against Human Colon Cancer Tumors Regardless of KRAS Mutation Status
Date:3/1/2011

REDWOOD CITY, Calif., March 1, 2011 /PRNewswire/ -- OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells, today announced the publication of preclinical data demonstrating that its lead candidate, OMP-21M18, inhibits tumor growth and reduces cancer stem cell frequency when administered alone or in combination with chemotherapy in human colorectal cancer tumors with or without KRAS mutations.  This study was published in the March 1, 2011 issue of Cancer Research, a publication of the American Association of Cancer Research.

"Using xenograft models developed at OncoMed, we observed that OMP-21M18 is equally efficacious against colon tumors with oncogenic KRAS mutations and colon tumors with a normal KRAS gene.  In contrast, cetuximab was inactive against KRAS mutant tumors," said Timothy Hoey, Ph.D., Senior Vice President, Cancer Biology of OncoMed Pharmaceuticals and a co-author of the paper.  "Further, OMP-21M18 was seen to reduce cancer stem cell frequency while promoting apoptosis in tumor cells and this activity was greatly enhanced when our agent was combined with chemotherapy.  These findings suggest that OMP-21M18 demonstrates potent anti-cancer activity in xenograft models of colorectal cancer with the potential to be an important treatment for this disease."

OMP-21M18 is a monoclonal antibody that blocks Delta-like 4 ligand (DLL4), an activator of Notch signaling, a pathway known to be important in stem cells and cancer.  Blocking DLL4 results in broad-spectrum anti-tumor activity via multiple mechanisms, including inhibiting cancer stem cell growth, promoting cell differentiation and disrupting angiogenesis.  OncoMed researchers conducted a series of experiments using the company's proprietary xenograft models to examine the efficacy of anti-DLL4 antibodies in KRAS-mutated and normal colorectal tumors derived from patients.  Treatment with anti-DLL4 w
'/>"/>

SOURCE OncoMed Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. OncoMed Chooses SynCo Bio Partners to Fill and Finish its Lead Antibody
2. SynCo Expands Agreement with OncoMed Pharmaceuticals to Manufacture Cancer Stem Cell Antibodies
3. Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
4. OncoMed Pharmaceuticals Awarded Five Therapeutic Discovery Project Grants Totaling $1.2 Million
5. OncoMed Pharmaceuticals Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5
6. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
7. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
8. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
9. Aida Announces Completion of Anti-Cancer Drug Phase Two Testing
10. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
11. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 /CNW/ - ... being recalled after Health Canada tests confirmed it contains ... risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health Distribution ... the product from retail stores across Canada ... purposes, including for weight loss and increased energy. ...
(Date:12/24/2014)...  Novastem, a leader in regenerative medicine, announces ... study for ischemic stroke at Clinica Santa Clarita. ... account for 87 percent of all stroke cases. ... study, entitled "Internal Research Protocol in Combination Therapy ... and Intrathecal Administration of Neural Stem Cells in ...
(Date:12/24/2014)... DUBLIN , Dec. 24, 2014  Actavis ... that the Company has received a complete response ... (FDA) for its New Drug Application (NDA) for ... for the treatment of hypertension.   Photo ... we are disappointed in the receipt of a ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
... Fla., Oct. 9 VitalRemedyMD, a physician-established company, ... improve the quality of traditional healthcare. "We are ... of Fresenius, armamentarium in helping patients with chronic ... VitalRemedyMD. A state-of-the-art medical food, VitalProteinRx is designed ...
... , ... Healthcare and HHC Nutrition Services will pay the United States $1.375 ... kickbacks and assistance under the guise of a sham durable medical ... that McKesson Corp., and its affiliate MediNet Corp. provided the kickbacks ...
Cached Medicine Technology:Fresenius Medical Care, N.A. Has Selected VitalRemedyMD's VitalProteinRx(TM) As Its Bar of Choice for Protein Replacement in Dialysis Patients 2Harborside Healthcare to Pay U.S. $1.375 Million to Resolve Allegations of Kickbacks and Sham Durable Medical Services 2
(Date:12/25/2014)... (PRWEB) December 26, 2014 This is ... of the global Sterilizers industry with a focus on ... the market status of the Sterilizers manufacturers and is ... and individuals interested in the industry. This report provides ... applications and manufacturing technology. In this part, the report ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
(Date:12/25/2014)... December 25, 2014 Product liability lawsuits ... hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward ... an Order issued in the U.S. District Court, Northern ... convene an open conference on January 7, 2015, at ... Courthouse in West Palm Beach, Florida. The Conference is ...
(Date:12/25/2014)... December 26, 2014 Recently, iFitDress.com, the popular ... women, has announced its new selection of black one-shoulder ... on sale now; they are available at discounted prices, up ... “The promotion will last for three weeks only. You know, ... Those who are interested in our new items can visit ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
Breaking Medicine News(10 mins):Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
... today announced,that it has finalized an agreement with U.K.-based ... with wound dressings,manufactured by AMS., Through this collaboration, ... testing of the use of GLYC-101 with AMS, wound ... phase of testing gives rise to,favorable results, or generates ...
... Professor Ian Frazer has won the 2008 Prime Minister,s ... UQ,s Diamantina Institute for Cancer, Immunology and Metabolic Medicine, ... Rudd at a special ceremony in the Great Hall, ... , The Prime Minister,s Prize for Science is the ...
... Pa., Oct. 17 Level III Trauma,Center Accreditation ... in,Pennsylvania for the period from November 1, 2008 ... South Jackson Street, Pottsville, PA, The Pennsylvania ... by the Emergency Medical Services Act (Act 1985-45).,The ...
... Regional Expansion With Mobile Healthy,Living Experience in Greater ... of Grains brand announced today,their expansion into the ... a Mobile Healthy Living Experience at select Hannaford ... simple, better decisions,to improve their lifestyle and diet. ...
... Part of Larger Health and,Nutrition Program, HACKETTSTOWN, ... is proud to be the first confectionery company ... (GDA) nutrition labeling on,all of its chocolate, non-chocolate ... redesigned to feature new graphics on the front ...
... for Joint-Pain Sufferers Who are Confused and Concerned, About ... Reveals Truth About Makeup of Joint ... 17 A new Web site,dedicated to helping women fight ... to help joint-pain sufferers take control of,their lives with a ...
Cached Medicine News:Health News:Glycotex Finalizes Collaboration Agreement with Advanced Medical Solutions 2Health News:Glycotex Finalizes Collaboration Agreement with Advanced Medical Solutions 3Health News:PM's science prize for Ian Frazer 2Health News:Level III Trauma Center Accreditation Status for Pennsylvania 2Health News:World of Grains(TM) - The Cookie That's One Bite Better Comes to a Store Near You 2Health News:World of Grains(TM) - The Cookie That's One Bite Better Comes to a Store Near You 3Health News:Mars First Confectionery Company to Launch Front-of-Pack Nutrition Labeling Globally 2Health News:Mars First Confectionery Company to Launch Front-of-Pack Nutrition Labeling Globally 3Health News:Mars First Confectionery Company to Launch Front-of-Pack Nutrition Labeling Globally 4Health News:Mars First Confectionery Company to Launch Front-of-Pack Nutrition Labeling Globally 5Health News:www.Joyn7030.com, A New Web Site Dedicated to Helping Women Fight Joint Pain, Launches 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: